Meniscus tears are one of the most frequent injuries in the knee. However, current meniscus repair treatment still remains challenging because of its poor tissue integration and low healing capacity. **MeniGel** provides a new solution by functionally repairing the meniscal lesions satisfying the biomechanical demands of the meniscus repair.

**Our clients**

About 750,000 meniscus surgeries are performed every year in the United States. Sports medicine, orthopedic clinics, veterinary clinics and related medical device companies and distributors will be our main clients.

**How will we make money?**

Our business is based on obtaining revenue by selling MeniGel, surgical instruments and related consumables. Also, training service for surgeons could be the additional revenue opportunity.

**Our expertise**

We have developed our highly adhesive material through a collaboration between experts in the fields of medicine, engineering, and biomedical and life sciences. A patent application has been filed and further developments are ongoing.

**Next steps**

We will perform preclinical studies to validate the concept of our product. This step includes comparison between the conventional surgery method and the hydrogel-incorporated surgery for meniscus tear repair. This would give us clear idea how our hydrogel improves meniscus repair. Furthermore, we will design the first prototype of medical instrument for injection and curing of our product. We are looking for funding sources and collaborations for clinical trials to speed up the process.